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Background. Nevirapine (NVP) can be safely and effectively administered once-daily but has not been assessed
in human immunodeficiency virus (HIV)–infected patients with tuberculosis (TB). We studied the safety and
efficacy of once-daily NVP, compared with efavirenz (EFV; standard therapy); both drugs were administered in
combination with 2 nucleoside reverse-transcriptase inhibitors.
Methods. An open-label, noninferiority, randomized controlled clinical trial was conducted at 3 sites in
southern India. HIV-infected patients with TB were treated with a standard short-course anti-TB regimen
(2EHRZ3/4RH3; [2 months of Ethambutol, Isoniazid, Rifampicin, Pyrazinamide / 4 months of Isoniazid and
Rifampicin] thrice weekly) and randomized to receive once-daily EFV at a dose of 600 mg or NVP at a dose of
400 mg (after 14 days of 200 mg administered once daily) with didanosine 250/400 mg and lamivudine 300 mg after
2 months. Sputum smears and mycobacterial cultures were performed every month. CD41 cell count, viral load,
and liver function test results were monitored periodically. Primary outcome was a composite of death, virological
failure, default, or serious adverse event (SAE) at 24 weeks. Both intent-to-treat and per protocol analyses were
done, and planned interim analyses were performed.
Results. A total of 116 patients (75% [87 patients] of whom had pulmonary TB), with a mean age of 36 years,
a median CD41 cell count of 84 cells/mm3, and a median viral load of 310 000 copies/mL, were randomized. At
24 weeks, 50 of 59 patients in the EFV group and 37 of 57 patients in the NVP group had virological suppression
(P5 .024). There were no deaths, 1 SAE, and 5 treatment failures in the EFV arm, compared with 5 deaths, 2 SAEs,
and 10 treatment failures in the NVP arm. The trial was halted by the data and safety monitoring board at the second
interim analysis. Favorable TB treatment outcomes were observed in 93% of the patients in the EFV arm and 84%
of the patients in the NVP arm (P 5 .058).
Conclusions. Compared with a regimen of didanosine, lamivudine, and EFV, a regimen of once-daily
didanosine, lamivudine, and NVP was inferior and was associated with more frequent virologic failure and death.
Clinical Trials Registration. NCT00332306.
Tuberculosis (TB) is often the first manifestation of
human immunodeficiency virus (HIV) infection in
countries with a high prevalence of TB [1]. Coinfected
patients presenting with TB are often immunosup-
pressed and in need of antiretroviral treatment (ART).
In 2009, it was estimated that, of the 9.4 million new
TB cases worldwide, approximately 1.1 million were in
individuals coinfected with HIV, and these cases ac-
counted for 27% of TB-related deaths. Because of rapid
scale-up of testing worldwide, an increasing number
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of coinfected patients are being identified [2]. TheWorld Health
Organization now recommends ART for all patients with TB
and HIV coinfection regardless of CD41 cell count, to be ini-
tiated within a few weeks of TB treatment [3–8]. Proposed
regimens include combinations of 2 nucleoside reverse-tran-
scriptase inhibitors (NRTIs) and a nonnucleoside reverse-tran-
scriptase inhibitor (NNRTI), with costs and toxicity varying
depending on the choice of drugs [8].
For treatment of TB in patients with HIV infection, regimens
that contain rifampicin throughout the treatment period have
better outcomes (lower treatment failure and recurrence rates)
than do nonrifampicin regimens [9–11]. However, simulta-
neous treatment of both infections is complicated by the fact
that rifampicin, a potent inducer of the hepatic cytochrome
P450 enzymes, leads to a reduction in levels of NNRTIs in blood
[12, 13]. Of the 2 widely available NNRTIs, efavirenz (EFV) is
the preferred drug for coadministration with rifampicin because
it is associated with less drug interaction and is administered
with once-daily dosing [14, 15]. However, nevirapine is the most
widely used NNRTI worldwide, because it is inexpensive, non-
teratogenic, and available in fixed-drug combinations. Although
nevirapine (NVP) can be administered once daily with efficacy
and safety equivalent to that associated with twice-daily treat-
ment in HIV-infected patients, no studies of once-daily treat-
ment have been conducted among patients receiving anti-TB
treatment (ATT) [16, 17]. Retrospective cohort analyses of pa-
tients initiating ART (twice-daily nevirapine) while receiving
ATT have had conflicting results with respect to virologic out-
comes [18, 19].
We performed a randomized controlled clinical trial to com-
pare the efficacy and safety of a once-daily ART regimen of di-
danosine, lamivudine, and NVP with a standard regimen of
didanosine, lamivudine, and EFV among patients with HIV-1
infection and TB. If NVP used once-daily in combination with
rifampicin were found to be safe and noninferior to EFV, such
a regimen would be practical, affordable, and lend itself to di-
rectly observed treatment. Drugs that had evidence for once-daily
use and were available in India in 2003 were selected for this trial.
METHODS
Study Design and Setting
This was an open label, parallel arm, randomized controlled
clinical trial. The study was conducted at 3 sites of the Tubercu-
losis Research Centre (TRC) in Chennai, Vellore, and Madurai,
located in southern India, during the periodMay 2006–June 2008.
Inclusion and Exclusion Criteria
HIV-infected patients who were at least 18 years of age with
newly diagnosed TB, were nonpregnant, and had CD41 cell
counts,250 cells/mm3 were eligible. Exclusion criteria included
previous ATT or ART for .1 month, HIV-2 infection, major
psychiatric illness, aspartate aminotransferase and alanine ami-
notransferase levels .2.5 times the upper limit of normal and
having a severe non–HIV-related disease. The protocol was
approved by the institutional and national ethics committees,
and written informed consent was obtained from all patients.
The trial was registered in the National Institutes of Health
Clinical Trials Registry, NCT 00332306, and the full protocol is
available upon request.
Recruitment and Randomization
At study entry, patients had a complete history and physical
examination, chest radiograph posterior-anterior view, and
laboratory investigations that included hematological analysis
(ABX Pentra60; Horiba ABX Diagnostics), CD41 cell counts
(Beckman Coulter Epics XL), HIV-1 RNA level (Roche Am-
plicor, version 1.5), blood glucose levels, and liver and renal
function tests (Olympus AU400). Three sputum specimens
(1 spot and 2 overnight samples) were collected for acid-fast
bacillus smear and culture, and relevant investigations were
performed for diagnosis of extra-pulmonary TB. Smears were
stained with auramine-rhodamine and examined by fluorescent
microscopy; sputum was processed by modified Petroff’s
method and cultured on Lowenstein-Jensen medium [20, 21].
Extra-pulmonary TB was diagnosed based on cyto- and histo-
pathological (for lymph node specimens) or radiographic and
biochemical (for pleural effusion specimens) parameters. All
microbiological and laboratory investigations were done by
technicians blinded to the treatment given.
Permuted block randomization (blocks of 8) was done cen-
trally using a computer-generated list of random numbers,
stratified by site and 2 levels of CD41 cell count (#150 vs
.150 cells/mm3) and viral load (#50 000 vs.50 000 copies/mL)
each. Allocation codes concealed in sealed, opaque, sequentially
numbered envelopes were prepared by statisticians and pro-
vided to each site for patient enrollment by study physicians.
Study Intervention
All patients received the standard national anti-tuberculosis
regimen with isoniazid, rifampicin, ethambutol, and pyr-
azinamide for the first 2 months followed by isoniazid and ri-
fampicin for the subsequent 4 months, thrice-weekly throughout.
Dosages of drugs were as follows: isoniazid, 600 mg; rifam-
picin, 450/600 mg for body weight , or $60 kg; ethambutol,
1200 mg; and pyrazinamide, 1500 mg. After the intensive
phase, patients were randomized to one of the anti-retroviral
regimens, along with the continuation phase of ATT. The
study regimen was didanosine, lamivudine, and nevirapine,
whereas the control regimen was didanosine, lamivudine, and
efavirenz. Dosages used were as follows: didanosine, 250/400 mg
for body weight , or $60 kg; lamivudine, 300 mg; efavirenz,
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600 mg; and nevirapine, 400 mg (after 14 days of 200 mg) once-
daily. Every batch of drugs was assayed to ensure quality [22].
All drugs were administered under direct observation in the
clinic 3 days a week and supplied to the patient for the re-
maining days. In addition to ATT and ART, patients received
1 tablet of trimethoprim-sulfamethoxazole at double strength,
pyridoxine 10 mg, and multivitamins daily, in combination
with psychosocial and adherence counseling.
Clinical and Laboratory Follow-up
Patients were followed up every month with a review of ad-
herence, new symptoms, and possible toxicity. Complete blood
counts, CD41 cell counts, and HIV-1 RNA levels were mea-
sured at 4, 16, and 24 weeks after ART initiation. Liver function
was assessed every 2 weeks until the eighth week and then once
every 12 weeks. Three specimens of sputum were collected each
month for smear and culture for Mycobacterium tuberculosis.
A chest radiograph was taken at the end of the intensive phase, at
the end of ATT, and in the event of clinical deterioration. Ad-
ditional investigations were done as per clinical indication.
Study Endpoints
The primary composite study endpoint was related to the effi-
cacy of the ART regimen at 24 weeks: death, HIV-1 RNA level
.400 copies/mL, default, or termination of study drug as a re-
sult of toxicity were considered unfavorable. With respect to
pulmonary TB, the response was considered favorable if all
sputum cultures were negative in the last 2 months of treatment.
Unfavorable responses to ATT included failure (clinical or
bacteriological), default, or death due to TB. For extra pulmo-
nary TB, favorable response was defined as improvement of
symptoms, regression of lymph nodes, and/or radiographic
improvement.
Statistical Analysis
We assumed a favorable virologic response rate of 90% at
24 weeks with the control (EFV) regimen and a noninferiority
margin of 15% for the NVP regimen. With a power of 80% and
a significance level of 5%, the sample size per group was 90,
allowing for a 20% loss due to death or loss to follow-up.
Both the intent-to-treat (ITT) and per-protocol analysis were
performed using SPSS software, version 11.3 (SPSS). For per-
protocol analysis, only patients with .90% adherence (esti-
mated by pill counts during surprise home visits and directly
observed treatment) were considered. The v2 test was used to
compare the proportion of patients who had a favorable re-
sponse and relative risk was calculated. Interim analyses were
planned after 25%, 50%, and 75% of enrolled patients com-
pleted 24 weeks of ART, to be reviewed by the data safety
monitoring board (DSMB). Prespecified stopping rules were
based on the O’Brien–Fleming boundary for significance, which
maintained an overall P value of .05 [23].
RESULTS
Baseline Characteristics
Five hundred and sixty-four patients with suspected TB and
HIV coinfection were screened; 122 met the initial inclusion
criteria and were enrolled. A total of 116 (93 men and 23
women) were randomized to an antiretroviral regimen at
2 months: 59 were randomized to the EFV regimen, and 57 were
randomized to the NVP regimen (Figure 1). The DSMB halted
enrollment to the study after the second interim analysis, be-
cause the difference in response between the regimens had
crossed the O’Brien–Fleming significance boundary.
At baseline, the 2 groups had similar demographic and clinical
characteristics (Table 1). Two-thirds of patients had intrathoracic
TB; radiographic lesions included parenchymal opacities, pleural
effusion, hilar adenopathy, and miliary TB. Baseline cultures
were positive for M. tuberculosis in 46 patients in the EFV arm
and 40 patients in the NVP arm. A total of 105 patients com-
pleted 24 weeks of follow-up after ART initiation, whereas 6
were lost to follow up and 5 died.
Treatment Outcomes
Primary Study Outcome (ITT). The proportion of patients
alive, on the same regimen, and with HIV RNA levels
,400 copies/mL was significantly higher with the EFV regi-
men (50 [85%] of 59 patients) than with the NVP regimen
(37 [65%] of 57) (P 5 .024). The point estimate of the dif-
ference in efficacy between the regimens was 20% (95%
confidence interval [CI], 11.2%–28.8%). Figure 2A shows the
absolute number of patients with detectable viral load . 400
copies/mL at various time points. The proportion with viral
load ,400 copies/mL was 70% and 63% at 4 weeks, 96% and
76% at 16 weeks, and 85% (95% CI, 76%–94%) and 65%
(95% CI, 53%–77%) at 24 weeks in the EFV and NVP arms,
respectively. The relative risk of treatment failure in the NVP
arm was 1.28 (95% CI, 1.03–1.6). There were 5 virological
failures and no deaths in the EFV arm versus 10 virological
failures and 5 deaths in the NVP arm. One patient terminated
EFV treatment because of psychosis, and 2 patients in the
NVP arm switched therapy to EFV because of Stevens–Johnson
syndrome. Three patients defaulted in each group.
Ninety-two percent of the EFV group and 93% of the NVP
group had.90% adherence to study drugs (P5 not significant)
and were included in the per-protocol analysis. Fifty (91%) of
55 patients in the EFV group (95% CI, 83%–99%) and Thirty-
six (70%) of 52 patients in the NVP group (95% CI, 58%–82%)
had an undetectable viral load at week 24 (P 5 .006).
Response to ATT. Baseline drug susceptibility results were
available for 78 patients: 3 isolates were resistant to isoniazid
alone, 3 isolates were resistant to streptomycin alone, and
1 patient had multidrug-resistant TB. At the end of intensive
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phase, sputum smears were negative in 82% of the patients,
whereas culture results were negative in 88% of the patients.
At the end of ATT, 55 patients (93%) in the EFV arm and
48 patients (84%) in the NVP arm had a favorable response
(P 5 .058). One patient experienced treatment failure and 3
patients defaulted in the EFV arm, whereas there were 3 deaths
(including in the patient with multidrug-resistant TB), 3
treatment failures (2 clinical failures and 1 bacteriological fail-
ure), and 3 defaulters in the NVP arm.
Change in Clinical and Laboratory Parameters. With
ATT and ART, patients in both regimens demonstrated signif-
icant increases in weight (with mean weight [6 standard de-
viation {SD}] increasing from 42.66 8.5 kg to 49.26 8.4 kg and
from 41.6 6 7.6 kg to 48.1 6 7.7 kg]); body mass index (BMI),
Figure 1. Trial profile.
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defined as the weight in kilograms divided by the square of
height in meters (with mean BMI [6 SD] increasing from 16.3
6 2.6 to 18.6 6 2.3 and from 16.3 6 2.3 to 18.9 6 2.4), and
hemoglobin level (with mean hemoglobin level [6 SD] in-
creasing from 11.4 6 1.8 g/dL to 12. 9 6 2.2 g/dL and from 9.5
6 2.0 g/dL to 12.7 6 2.7 g/dL) in the EFV and NVP groups,
respectively (P , .05 for all). There were no significant changes
in mean liver or renal function parameters or serum amylase
levels in either arm (results not shown). Figure 2B shows
the change in CD41 cell count; the mean increase (6SD) at
24 weeks was 215 6 101 cells/mm3and 201 6 101 cells/mm3 in
the EFV and NVP groups, respectively (P 5 not significant).
Adverse Drug Reactions. There were a total of 57 adverse
drug reactions in the EFV arm: 44 cases of grade I or grade II
dizziness, 6 cases of rash, 5 cases of gastrointestinal symptoms
(including 2 of jaundice that required temporary withholding
of drugs), and 1 case each of psychosis and peripheral neurop-
athy (requiring substitution of the offending drug). In the NVP
arm, there were 33 adverse drug reactions, including 16 neuro-
logical, 3 gastrointestinal, and 14 cutaneous events (including
2 cases that required substitution with a different drug) (Table 2).
Serious adverse events included 2 cases of severe peripheral
neuropathy, secondary to receipt of didanosine, which required
switching treatment to tenofovir (1 case in each study arm),
1 case of EFV-induced psychosis, and 2 cases of Stevens–Johnson
syndrome associated with receipt of NVP (Table 3). There were
no deaths attributable to adverse drug reactions.
Immune Reconstitution Inflammatory Syndrome. Twenty-
five (21%) of 116 patients had symptoms suggestive of immune
reconstitution inflammatory syndrome (IRIS). There was ra-
diographic deterioration in 10 patients and extrapulmonary
manifestations in 15 (8 patients had lymph node enlargement,
1 patient had tuberculoma, and 6 patients had pleural effusion).
Table 1. Pretreatment Characteristics of Patients in Intent-to-Treat Analysis
Characteristic of study subjects Efavirenz regimen (n 5 59) Nevirapine regimen (n 5 57)
Age, mean years (6SD) 34.4 6 7.5 37.8 6 7.7
Male sex, no. (%) of subjects 49 (83) 44 (77)
BMI, mean value (6SD) 16.3 6 2.6 16.4 6 2.4
CD41 cell count, median cells/mm3 (IQR) 85 (47–85) 83 (33–135)
Viral load, median copies/mL (IQR) 362 000 (41 575–750 000) 282 000 (128 500–649 500)
Pulmonary TB
Sputum culture positive, no. (%) of subjects 43 (73) 37 (65)
Sputum culture negative, no. of subjects 2 5
Extra-pulmonary TB, no. of subjects
Overall 14 15
Culture positive (lymph node/pleural effusion) 3 3
Culture negative 11 12
Abbreviations: BMI, body mass index defined as the weight in kilograms divided by the square of height in meters; IQR, interquartile range; SD, standard
deviation; TB, tuberculosis.
Figure 2. A, Virological response to treatment for patients available for
evaluation over time (no. of patients with viral load .400 copies/mL).
B, Immunological response to treatment (mean CD41 cell count) over
time for all evaluable patients.
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Six patients became asymptomatic without any intervention, 10
patients received anti-inflammatory drugs, and 9 patients re-
ceived a course of corticosteroids.
Deaths. All 5 deaths in our study were related to neuro-
logical complications of HIV infection: 2 were due to neuro-
encephalopathy, 1 was due to cerebellar syndrome, 1 was due
to toxoplasmosis with disseminated M. kansassi infection, and
1 was due to possible TB meningitis. Although 3 patients died
during the first month of ART, 2 died in the fifth month. None
of the deaths were considered to be due to IRIS, although this
could not be definitively ruled out.
DISCUSSION
This open-label, randomized clinical trial demonstrated that
didanosine, lamivudine, and NVP administered once daily was
inferior (65% efficacy) to didanosine, lamivudine, and EFV (85%
efficacy) among HIV-infected patients receiving concomitant
anti-TB therapy. Per-protocol analysis among patients with
.90% treatment adherence confirmed the results, with efficacy
of 70% and 91%, respectively. No previous randomized trial
has compared once-daily NVP and EFV among patients with
HIV infection and TB, although most programs and clinicians
prefer the use of EFV because of pharmacokinetic and safety
reasons [8, 24–26].
Two retrospective cohort studies in South Africa and Thai-
land among patients starting ART with concurrent TB reported
lower rates of virologic suppression with NVP, compared with
EFV [18, 19]. Furthermore, a regimen of didanosine, lamivudine,
and EFV has excellent results in terms of both virological effi-
cacy and safety when used with and without ATT [27–29].
Although clinical trials have demonstrated that once-daily NVP
is as effective as twice-daily administration, none have tested its
use among patients with concomitant TB [14, 15].
Table 2. Incidence and Severity of Adverse Events in the Study Population, by Regimen
Efavirenz regimen, by grade Nevirapine regimen, by grade
Adverse event Total I II III IV Total I II III IV
Neurological 46 35 9 1 1 16 9 6 1
Paraesthesia 11 4 1 (D)a 9 2 1 (D)a
Vivid dreams 3 1
Dizziness 21 5 3
Major depression 1 (D)b
Gastrointestinal 5 1 2 2 3 1 1 1
Abdominal pain 1 1 1 (T)
Vomiting 2 1
Hepatitis/jaundice 2 (T)
Cutaneous 6 5 1 14 9 2 1 2
Stevens Johnson syndrome 2 (D)c
Itching 3 1 8 2
Rash 2 1 1
Total 57 41 12 1 3 33 19 9 2 3
Abbreviations: D, terminated and replaced with different drug; ddI, didanosine; EFV, efavirenz; NVP, nevirapine, T, temporarily withheld.
a ddI replaced with tenofovir.
b EFV replaced with NVP.
c NVP replaced with EFV.
Table 3. Drug-Induced Serious Adverse Events (SAEs), by Regimen
Patient
Trial
regimen Offending drug Diagnosis Action taken
Month of
SAE Outcome
1 NVP NVP Steven-Johnson syndrome Switched to EFV 3 Resolved
2 NVP NVP Steven-Johnson syndrome Switched to EFV 1 Resolved
3 NVP Possibly ddI Possible pancreatitis; possible gastritis ART withheld 2 Improved
4 NVP ddI Sensory/motor peripheral neuropathy Switched to tenofovir 3 Improved
5 EFV ddI Sensory/motor peripheral neuropathy Switched to tenofovir 3 Improved
6 EFV EFV Psychosis Switched to NVP 1 Resolved
Abbreviations: ART, antiretroviral therapy; ddI, didanosine; EFV, efavirenz; NVP, nevirapine.
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Response to TB treatment was marginally better in the EFV
arm than in the NVP arm. Concomitant ART improves TB
outcomes; we had earlier demonstrated a favorable response
of 83% in ART-naive patients using the same TB regimen [30].
Recent studies have demonstrated lower mortality among
coinfected patients (CD41 cell count, ,500 cells/mm3) who
initiated ART early, compared with those for whom ART was
deferred [4, 5]. The Cambodian Early versus Late Introduction
of Antiretroviral drugs (CAMELIA) and ACTG522I trials have
demonstrated the benefit of earlier initiation of ART therapy in
patients with TB and HIV coinfection with very low CD41 cell
counts (,50 cells/mm3) [31, 32]. In our study, we had
37 patients with a baseline CD41 cell count,50 cells/mm3 (15
in the EFV arm and 22 in the NVP arm). There was no mor-
tality among patients in the EFV group despite low CD41 cell
counts, whereas the outcome in the NVP arm was probably
related to the performance of the regimen (which resulted in
subtherapeutic NVP levels during the lead-in phase) and not
the timing of ART initiation. Therefore, although earlier ART
initiation might have improved outcomes, it is unlikely to have
altered the difference in response between the 2 regimens,
which was the primary question addressed by this study.
The overall incidence of adverse events in our trial was low,
and most were easily managed. The most common adverse ef-
fects were dizziness and sleep disturbances associated with re-
ceipt of EFV; the majority of adverse effects were mild and
subsided within the first few days of treatment. There were 2
cases of grade III/IV hepatotoxicity in the EFV arm, which im-
proved after temporary withdrawal of drugs. In previous co-
horts, reported rates of hepatotoxicity have been low and
comparable between EFV and NVP when those drugs are ad-
ministered in combination with rifampicin, although rates have
been higher than among patients without TB [26, 33]. However,
peripheral neuropathy was of concern and may have been ag-
gravated by the concomitant use of didanosine and isoniazid
among patients with advanced HIV disease. Although most
patients responded to symptomatic treatment, which included
analgesics, nonsteroidal anti-inflammatory drugs, high-dose
pyridoxine, and carbamezapine, 2 patients required the sub-
stitution of didanosine with tenofovir. Although cutaneous re-
actions have been reported to be more common in patients who
receive once-daily NVP, these were mostly mild in our study;
2 patients with NVP-induced Stevens–Johnson syndrome re-
covered with symptomatic treatment and tolerated EFV well
later, which was the only treatment option available [34].
Primary drug resistance to antiretroviral drugs was negligible
among this population. At the time of treatment failure, V106M
and Y181C were the major NNRTI mutations, whereas M184V
and L741/V were the common NRTI mutations [35].
The strengths of our study include the generalizability of
the study findings, given the degree of immunosuppression at
baseline, which is typical for TB and HIV coinfection cohorts in
resource-limited settings. The comparability of the randomized
groups, the close clinical and laboratory monitoring, oversight
by DSMB and ethics committees, the observation of treatment
thrice weekly, the high rates of adherence to treatment, and the
extensive follow-up are other strengths. Limitations include the
early stopping of the trial by the DSMB, which limits the con-
clusions that can be drawn; however, the halting of the trial was
based on prespecified stopping rules. The use of tenofovir in-
stead of didanosine may have improved tolerability, but cost
considerations and the availability of generics determined the
choice of drugs. Furthermore, ART was not used during the
intensive phase of ATT. Now evidence suggests that patients
with CD41 cell counts ,50 cells/mm3 should initiate ART
during the first weeks of ATT [31]. Furthermore, NVP could
have been initiated without the lead-in phase, because liver
enzymes were in an induced state because of rifampicin; how-
ever, safety concerns and a lack of pilot data dissuaded us from
following this option. A recent report on rifampicin-treated
patients from Thailand showed that, although a 200-mg NVP
lead-in dose led to significant short-term suboptimal NVP
concentrations, a higher lead-in of dose of 400 mg followed by
600 mg per day was associated with a high rate of NVP hyper-
sensitivity [36]. Future research should explore the possibilities
of using rifabutin instead of rifampicin for TB treatment in these
patients. We used thrice-weekly therapy because this is the
standard TB treatment regimen in India, although recent evi-
dence suggests that this regimen may be suboptimal for patients
infected with HIV [37].
Our study contributes to the growing body of literature on
optimal treatment of HIV-infected patients with TB [37, 38].
Although the once-daily treatment concept is attractive because
of convenience, greater adherence among patients, and the
possibility of directly observed therapy, our results indicate that
NVP cannot be used once daily in combination with rifampicin-
containing ATT. The once-daily regimen of didanosine, lam-
ivudine, and EFV was safe, efficacious, and well-tolerated and had
a favorable resistance profile, with low emergence of thymidine-
associated mutations among patients with virologic failure.
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